All News

pill pillbox adherence

Adherence to Medication - Predictive Factors in RA

d Jack Cush, MD

The numbers on treatment adherence is disappointingly low in RA, with a number of psychological, communication and logistical factors that outweigh the potentially negative influence of sociodemographic or clinical factors.

Read Article
fever2.jpg

When to Stop Biologics in Systemic JIA?

d Jack Cush, MD

Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.

Read Article
RheumNow Podcast square

T2T Debate - A Prologue with Dr. Marty Bergman

d Jack Cush, MD

Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.



Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.

Read Article
Increased risk death in 310 scleroderma pts: 63 diffuse SSc, 279 limited dz & 33 sine scleroderma (SMR = 1.88). Reduced survival at 10 yrs (78%) & 15 yrs(61%). 69 deaths, 46% in diffuse PSS - due to ILD, PHA, and GI involvement https://t.co/w300etSls2

Links:

Dr. John Cush RheumNow ( View Tweet)

NYC Hosp for Special Surgery is the 1st to use a "smart" knee arthroplasty - TKR with a smart sensor capable of monitoring steps, speed, range of motion & other knee functions fed back to the orthopedist = called Persona IQ, FDA authorized https://t.co/QR49JC7oCz

Links:

Dr. John Cush RheumNow ( View Tweet)

Pre-clinical RA: starting off the wrong foot https://t.co/LA2dLaAM6C https://t.co/lgKFY0zDeq

Links:

Dr. John Cush RheumNow ( View Tweet)
Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found. https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

Dr. John Cush RheumNow ( View Tweet)
Fibromyalgia pts are prone to suicidal ideation (29.6%; OR 9.1), attempts (5.7%; OR 3.1), & events (OR 1.38), but significance lost when correcting for psych illness. Risk assoc w/ work, dz severity, obesity, addiction, chronic pain & co-morbidities. https://t.co/jjiZ5iZBjP https://t.co/cuCsKKcOj7

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: TNF inhibitors and radiographic progression in axSpA A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease. https://t.co/H0Fr54PwOP https://t.co/tFZJUr1j4B

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI:CDC and the ICD-10 Coordination and Maintenance Committee has assigned a diagnostic code for non-radiographic axial spondyloarthritis (nr-axSpA) == M45.A

Dr. John Cush RheumNow ( View Tweet)

FDA Puts Boxed Warnings on JAK Inhibitors Based on the safety review of tofacitinib in Pfizer's Oral Surveillance study, the FDA has formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor. https://t.co/bXZ4Yedyyv https://t.co/tsvHOtIEK0

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risks associated with mortality in VEXAS https://t.co/mpAc5shaMq https://t.co/FdOQcfwusp

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Zoom Fatigue is real. Study shows fatigue is from being on-cam that triggers self-presentation - the needs to monitor how you look to others; more common in women. Suggest: reduce monitor/image size & Turn off Self view (avoid self evaluation) https://t.co/vS8tJv9Kpd https://t.co/F7mHdYgOXy

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast up! Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology. Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022. https://t.co/oe6hsAq2KG https://t.co/1sbTmd9cnV

Links:

Dr. John Cush RheumNow ( View Tweet)
Download Available! The Scary Side of Steroid. Log in and download today. https://t.co/sYVWGTVHgx https://t.co/NIbi49SJEo

Links:

Dr. John Cush RheumNow ( View Tweet)
AURORA 2 results were presented at #ACR21 - a continuation study of voclosporin in 116 active Lupus Nephritis pts randomized to either PBO or voclosporin. After 36 mos the VOC group had stable GFR and reduction in proteinuria https://t.co/O7G1dCIzbP

Links:

Dr. John Cush RheumNow ( View Tweet)

ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our blog by Dr. Kathryn Dao ( @KDAO2011) on "Redefining Aging." https://t.co/GbE77GTa0y https://t.co/e2GYETqsUR

Links:

Dr. John Cush RheumNow ( View Tweet)
CBD and Opioids in PsA : Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the ACR21 annual meeting. https://t.co/ZATSfzqj51 https://t.co/dhFwgS9b6J

Links:

Dr. John Cush RheumNow ( View Tweet)
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? https://t.co/RbOlrnW54O https://t.co/iDlqwv32zs

Links:

Dr. John Cush RheumNow ( View Tweet)
×